DDInter535 DDInter1070
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
Diazoxide {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Linagliptin
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Diazoxide {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Diazoxide {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Metamfetamine
Metamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Diazoxide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Diazoxide {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linagliptin
Diazoxide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Linagliptin
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Linagliptin
Diazoxide {u} (Compound) binds {v} (Gene) ATP1A1
ATP1A1 {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Diazoxide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Linagliptin (Compound)
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Diazoxide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Alogliptin (Compound) and Alogliptin (Compound) resembles Linagliptin (Compound)
Diazoxide (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Metamfetamine (Compound) and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Diazoxide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Diazoxide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Linagliptin
Diazoxide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Linagliptin (Compound)
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Linagliptin (Compound)
Diazoxide (Compound) binds ATP1A1 (Gene) and ATP1A1 (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin